Clinical Trial Update: Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) [Phase 1]

View source ↗

Summary

Open-label Phase 1 study assessing potential drug-drug interactions with dupilumab in adults with moderate-to-severe atopic dermatitis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED